CN Patent

CN105188699B — 恩杂鲁胺的固态形式及其制备方法和用途

Assigned to Ni Yun · Expires 2017-04-26 · 9y expired

What this patent protects

本发明涉及恩杂鲁胺的新固态形式，与现有技术相比，本发明恩杂鲁胺的新固态形式具有一种或多种改进的特性，例如良好的溶解度、溶解速度，好的稳定性、有利的加工与处理特性、适于固体制剂应用等。本发明还涉及所述恩杂鲁胺的新固态形式的制备方法、其药物组合物及其用于制备治疗转移性去势耐受前列腺癌等疾病的药物中的用途。

USPTO Abstract

本发明涉及恩杂鲁胺的新固态形式，与现有技术相比，本发明恩杂鲁胺的新固态形式具有一种或多种改进的特性，例如良好的溶解度、溶解速度，好的稳定性、有利的加工与处理特性、适于固体制剂应用等。本发明还涉及所述恩杂鲁胺的新固态形式的制备方法、其药物组合物及其用于制备治疗转移性去势耐受前列腺癌等疾病的药物中的用途。

Drugs covered by this patent

Xtandi (enzalutamide) · Astellas Pharma

Patent Metadata

Patent number: CN105188699B
Jurisdiction: CN
Classification: —
Expires: 2017-04-26
Drug substance claim: No
Drug product claim: No
Assignee: Ni Yun
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.